Try a new search

Format these results:

Searched for:

person:gondat01

in-biosketch:true

Total Results:

122


Pancreatic Cysts

Gonda, Tamas A; Cahen, Djuna L; Farrell, James J
PMID: 39231345
ISSN: 1533-4406
CID: 5688012

Somatic Mutational Analysis in EUS-Guided Biopsy of Pancreatic Adenocarcinoma: Assessing Yield and Impact

Dong, Sue; Agarunov, Emil; Fasullo, Matthew; Kim, Ki-Yoon; Khanna, Lauren; Haber, Gregory; Janec, Eileen; Simeone, Diane; Oberstein, Paul; Gonda, Tamas
OBJECTIVES/OBJECTIVE:We sought to determine the yield of somatic mutational analysis from EUS-guided biopsies of pancreatic adenocarcinoma compared to that of surgical resection and to assess the impact of these results on oncologic treatment. METHODS:We determined the yield of EUS sampling and surgical resection. We evaluated the potential impact of mutational analysis by identifying actionable mutations and its direct impact by reviewing actual treatment decisions. RESULTS:Yield of EUS sampling was 89.5%, comparable to the 95.8% yield of surgical resection. Over a quarter in the EUS cohort carried actionable mutations, and of these, over one in six had treatment impacted by mutational analysis. CONCLUSIONS:EUS sampling is nearly always adequate for somatic testing and may have substantial potential and real impact on treatment decisions.
PMID: 38546128
ISSN: 1572-0241
CID: 5645102

A Blueprint for a Comprehensive, Multidisciplinary Pancreatic Cancer Screening Program

Fasullo, Matthew; Simeone, Diane; Everett, Jessica; Agarunov, Emil; Khanna, Lauren; Gonda, Tamas
PMID: 37782292
ISSN: 1572-0241
CID: 5691062

Epigenetic therapeutic strategies in pancreatic cancer

Orlacchio, Arturo; Muzyka, Stephen; Gonda, Tamas A
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies, characterized by its aggressiveness and metastatic potential, with a 5-year survival rate of only 8-11%. Despite significant improvements in PDAC treatment and management, therapeutic alternatives are still limited. One of the main reasons is its high degree of intra- and inter-individual tumor heterogeneity which is established and maintained through a complex network of transcription factors and epigenetic regulators. Epigenetic drugs, have shown promising preclinical results in PDAC and are currently being evaluated in clinical trials both for their ability to sensitize cancer cells to cytotoxic drugs and to counteract the immunosuppressive characteristic of PDAC tumor microenvironment. In this review, we discuss the current status of epigenetic treatment strategies to overcome molecular and cellular PDAC heterogeneity in order to improve response to therapy.
PMID: 38359967
ISSN: 1937-6448
CID: 5633882

Hemospray® (hemostatic powder TC-325) as monotherapy for acute gastrointestinal bleeding: a multicenter prospective study

Papaefthymiou, Apostolis; Aslam, Nasar; Hussein, Mohamed; Alzoubaidi, Durayd; Gross, Seth A; Serna, Alvaro De La; Varbobitis, Ioannis; Hengehold, Tricia A; López, Miguel Fraile; Fernández-Sordo, Jacobo Ortiz; Rey, Johannes W; Hayee, Bu; Despott, Edward J; Murino, Alberto; Moreea, Sulleman; Boger, Phil; Dunn, Jason M; Mainie, Inder; Mullady, Daniel; Early, Dayna; Latorre, Melissa; Ragunath, Krish; Anderson, John T; Bhandari, Pradeep; Goetz, Martin; Kiesslich, Ralf; Coron, Emmanuel; Santiago, Enrique Rodríguez De; Gonda, Tamas A; O'Donnell, Michael; Norton, Benjamin; Telese, Andrea; Simons-Linares, Roberto; Haidry, Rehan
BACKGROUND/UNASSIGNED:Hemostatic powders are used as second-line treatment in acute gastrointestinal (GI) bleeding (AGIB). Increasing evidence supports the use of TC-325 as monotherapy in specific scenarios. This prospective, multicenter study evaluated the performance of TC-325 as monotherapy for AGIB. METHODS/UNASSIGNED:Eighteen centers across Europe and USA contributed to a registry between 2016 and 2022. Adults with AGIB were eligible, unless TC-325 was part of combined hemostasis. The primary endpoint was immediate hemostasis. Secondary outcomes were rebleeding and mortality. Associations with risk factors were investigated (statistical significance at P≤0.05). RESULTS/UNASSIGNED:One hundred ninety patients were included (age 51-81 years, male: female 2:1), with peptic ulcer (n=48), upper GI malignancy (n=79), post-endoscopic treatment hemorrhage (n=37), and lower GI lesions (n=26). The primary outcome was recorded in 96.3% (95% confidence interval [CI]: 92.6-98.5) with rebleeding in 17.4% (95%CI 11.9-24.1); 9.9% (95%CI 5.8-15.6) died within 7 days, and 21.7% (95%CI 15.6-28.9) within 30 days. Regarding peptic ulcer, immediate hemostasis was achieved in 88% (95%CI 75-95), while 26% (95%CI 13-43) rebled. Higher ASA score was associated with mortality (OR 23.5, 95%CI 1.60-345; P=0.02). Immediate hemostasis was achieved in 100% of cases with malignancy and post-intervention bleeding, with rebleeding in 17% and 3.1%, respectively. Twenty-six patients received TC-325 for lower GI bleeding, and in all but one the primary outcome was achieved. CONCLUSIONS/UNASSIGNED:TC-325 monotherapy is safe and effective, especially in malignancy or post-endoscopic intervention bleeding. In patients with peptic ulcer, it could be helpful when the primary treatment is unfeasible, as bridge to definite therapy.
PMCID:11226744
PMID: 38974074
ISSN: 1108-7471
CID: 5732192

Radiomics Boosts Deep Learning Model for IPMN Classification

Yao, Lanhong; Zhang, Zheyuan; Demir, Ugur; Keles, Elif; Vendrami, Camila; Agarunov, Emil; Bolan, Candice; Schoots, Ivo; Bruno, Marc; Keswani, Rajesh; Miller, Frank; Gonda, Tamas; Yazici, Cemal; Tirkes, Temel; Wallace, Michael; Spampinato, Concetto; Bagci, Ulas
Intraductal Papillary Mucinous Neoplasm (IPMN) cysts are pre-malignant pancreas lesions, and they can progress into pancreatic cancer. Therefore, detecting and stratifying their risk level is of ultimate importance for effective treatment planning and disease control. However, this is a highly challenging task because of the diverse and irregular shape, texture, and size of the IPMN cysts as well as the pancreas. In this study, we propose a novel computer-aided diagnosis pipeline for IPMN risk classification from multi-contrast MRI scans. Our proposed analysis framework includes an efficient volumetric self-adapting segmentation strategy for pancreas delineation, followed by a newly designed deep learning-based classification scheme with a radiomics-based predictive approach. We test our proposed decision-fusion model in multi-center data sets of 246 multi-contrast MRI scans and obtain superior performance to the state of the art (SOTA) in this field. Our ablation studies demonstrate the significance of both radiomics and deep learning modules for achieving the new SOTA performance compared to international guidelines and published studies (81.9% vs 61.3% in accuracy). Our findings have important implications for clinical decision-making. In a series of rigorous experiments on multi-center data sets (246 MRI scans from five centers), we achieved unprecedented performance (81.9% accuracy). The code is available upon publication.
PMCID:10810260
PMID: 38274402
CID: 5737532

The Use of Integrated Molecular Testing in the Assessment and Management of Pancreatic Cysts

Kirschenbaum, Joshua D; Gonda, Tamas A
PURPOSE OF REVIEW/OBJECTIVE:As abdominal imaging becomes more sensitive and regularly used, pancreatic cystic lesions (PCLs) are being diagnosed more frequently. A small but clinically significant minority of these lesions have a predisposition to either harbor malignancy or undergo malignant transformation. This review highlights the current state and performance of cystic fluid biomarkers and how they may be incorporated into management. RECENT FINDINGS/RESULTS:Among the major domains of molecular testing for PCLs, DNA based analyses have demonstrated the highest accuracy in identifying cyst type and have the most data to support their clinical use. However, epigenetic and protein biomarker based molecular assessments have emerged with the potential to complement DNA based approaches. In addition, recent studies have increasingly demonstrated the value associated with combinations of mutations and other biomarkers in identifying higher grade mucinous cystic lesions. We present the performance of individual biomarkers in cyst fluid analysis with an emphasis on an algorithmic approach to improve the accurate identification of both cyst type and risk of malignant transformation.
PMID: 37407751
ISSN: 1534-312x
CID: 5539272

Author Correction: Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment

Werba, Gregor; Weissinger, Daniel; Kawaler, Emily A; Zhao, Ende; Kalfakakou, Despoina; Dhara, Surajit; Wang, Lidong; Lim, Heather B; Oh, Grace; Jing, Xiaohong; Beri, Nina; Khanna, Lauren; Gonda, Tamas; Oberstein, Paul; Hajdu, Cristina; Loomis, Cynthia; Heguy, Adriana; Sherman, Mara H; Lund, Amanda W; Welling, Theodore H; Dolgalev, Igor; Tsirigos, Aristotelis; Simeone, Diane M
PMID: 37400453
ISSN: 2041-1723
CID: 5539082

Advances in the Diagnosis and Treatment of Pancreatic Cystic Neoplasms [Editorial]

Gonda, Tamas A
PMID: 37245943
ISSN: 1558-1950
CID: 5541872

Prognostic Factors for Non-anastomotic Biliary Strictures Following Adult Liver Transplantation: A Systematic Review and Meta-Analysis

Fasullo, Matthew; Ghazaleh, Sami; Sayeh, Wasef; Vachhani, Ravi; Chkhikvadze, Tamta; Gonda, Tamas; Janec, Eileen; Khanna, Lauren; Haber, Gregory; Shah, Tilak
INTRODUCTION/BACKGROUND:The development of non-anastomotic biliary strictures (NAS) following orthotopic adult liver transplantation (OLT) is associated with significant morbidity. We performed a systematic review and meta-analysis to identify all prognostic factors for the development of NAS. METHODS:A systematic review was conducted following preferred reporting items for systematic reviews and meta-analyses (PRISMA) and the meta-analysis of observational studies in epidemiology (MOOSE) guidelines. We used the Newcastle-Ottawa scale to assess the quality of the included studies. Using the random-effects model, we calculated the weighted pooled odds ratios (OR), mean differences (MD), hazard ratios (HR), and 95% confidence intervals (CI) of the risk factors. RESULTS:Based on 19 international studies that included a total of 8269 adult LT patients, we calculated an 8% overall incidence of NAS. In this study, 7 potential prognostic factors were associated with a statistically significant hazard ratio for NAS in pooled analyses including (1) DCD donors compared to DBD donors (2) PSC as an indication for a liver transplant (3) Roux-en-Y bile duct reconstruction compared to duct-to-duct reconstruction (4) hepatic artery thrombosis (5) longer cold ischemia time (6) longer warm ischemia time (7) and total operative times. CONCLUSION/CONCLUSIONS:In this systematic review and meta-analysis, we identified 7 prognostic factors for the development of NAS following OLT. These findings might lay the groundwork for development of diagnostic algorithms to better risk stratify patients at risk for development of NAS.
PMID: 36757492
ISSN: 1573-2568
CID: 5420922